Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
108.48
+0.69 (0.64%)
Aug 21, 2026, 9:50 AM EDT - Market open
Spyre Therapeutics Employees
Spyre Therapeutics had 125 employees as of June 30, 2026. The number of employees increased by 38 or 43.68% compared to the same quarter last year.
Employees
125
Change
38
Growth
43.68%
Revenue / Employee
n/a
Profits / Employee
-$1,201,704
Market Cap
9.57B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 125 | 38 | 43.68% |
| Mar 31, 2026 | 112 | 39 | 53.42% |
| Dec 31, 2025 | 102 | 37 | 56.92% |
| Sep 30, 2025 | 95 | 35 | 58.33% |
| Jun 30, 2025 | 87 | 27 | 45.00% |
| Mar 31, 2025 | 73 | 43 | 143.33% |
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Sep 30, 2024 | 60 | 46 | 328.57% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Jun 30, 2023 | 14 | -78 | -84.78% |
| Mar 31, 2023 | 61 | -38 | -38.38% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Sep 30, 2022 | 69 | -21 | -23.33% |
| Jun 30, 2022 | 92 | 1 | 1.10% |
| Mar 31, 2022 | 99 | 11 | 12.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| ImmunityBio | 691 |
| Crinetics Pharmaceuticals | 594 |
| Vaxcyte | 507 |
| Immunovant | 315 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 273 |
| Summit Therapeutics | 265 |
SYRE News
- 13 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 15 days ago - Spyre Therapeutics price target raised to $130 from $100 at Wedbush - TheFly
- 16 days ago - Spyre Therapeutics price target raised to $120 from $90 at Baird - TheFly
- 16 days ago - Spyre Therapeutics price target raised to $130 from $115 at Guggenheim - TheFly
- 16 days ago - Spyre Therapeutics price target raised to $115 from $90 at Wells Fargo - TheFly
- 16 days ago - Spyre Therapeutics reports Q2 EPS (36c), consensus (75c) - TheFly
- 16 days ago - Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 17 days ago - Spyre Therapeutics Quarterly report: Q2 2026 - Filings